Last reviewed · How we verify
HLD100
At a glance
| Generic name | HLD100 |
|---|---|
| Also known as | Dextroamphetamine sulfate, delayed release/extended release |
| Sponsor | Ironshore Pharmaceuticals and Development, Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD (PHASE2)
- A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HLD100 CI brief — competitive landscape report
- HLD100 updates RSS · CI watch RSS
- Ironshore Pharmaceuticals and Development, Inc portfolio CI